GlassScriptPhysician profile
Gisele Kabbach
NPI 1255795076
$2,494.18
in general payments reported to CMS, 2019-2025
23 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.82 · 2022: $125 · 2023: $449 · 2024: $410 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $74.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.50 |
| Education | $74.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $465.31 | 2024-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.80 | 2023-2025 | Ofev, Jascayd |
| Inari Medical, INC. | $233.75 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Galvanize Therapeutics, INC | $219.77 | 2025 | Aliya System |
| Genzyme Corporation | $217.97 | 2022-2025 | |
| Insmed, INC. | $121.95 | 2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $118.09 | 2023-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $89.54 | 2024-2025 | Winrevair, Keytruda |
| Amgen INC. | $88.10 | 2024-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $86.70 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $85.64 | 2025 | Zepbound |
| Electromed, INC. | $81.49 | 2025 | Smartvest |
| Grifols USA, LLC | $67.73 | 2024-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $65.11 | 2025 | Yupelri |
| Mylan Specialty L.P. | $59.26 | 2024 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Pulmonx Corporation | $48.09 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Vifor Pharma, INC. | $43.73 | 2024-2025 | Zemaira |
| Astrazeneca Pharmaceuticals LP | $36.00 | 2024-2025 | Fasenra |
| Philips North America LLC | $18.96 | 2025 | Vest Therapy Und |
| United Therapeutics Corporation | $16.79 | 2025 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 2019 | |
| Cmp Pharma, INC. | $15.10 | 2023 | Carospir, Norliqva, Tadliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gisele Kabbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.